GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Suisse Corp (OTCPK:CSUI) » Definitions » Sloan Ratio %

Cannabis Suisse (Cannabis Suisse) Sloan Ratio % : 0.00% (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cannabis Suisse Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Cannabis Suisse's Sloan Ratio for the quarter that ended in Feb. 2024 was 0.00%.

As of Feb. 2024, Cannabis Suisse has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Cannabis Suisse Sloan Ratio % Historical Data

The historical data trend for Cannabis Suisse's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Suisse Sloan Ratio % Chart

Cannabis Suisse Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23
Sloan Ratio %
Get a 7-Day Free Trial -24.62 - - - -

Cannabis Suisse Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cannabis Suisse's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Suisse's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Suisse's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Suisse's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Cannabis Suisse's Sloan Ratio % falls into.



Cannabis Suisse Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Cannabis Suisse's Sloan Ratio for the fiscal year that ended in May. 2023 is calculated as

Sloan Ratio=(Net Income (A: May. 2023 )-Cash Flow from Operations (A: May. 2023 )
-Cash Flow from Investing (A: May. 2023 ))/Total Assets (A: May. 2023 )
=(-0.352--0.164
-0)/0.346
=-54.34%

Cannabis Suisse's Sloan Ratio for the quarter that ended in Feb. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Feb. 2024 )
=(-0.255--0.061
-0)/0.526
=-36.88%

Cannabis Suisse's Net Income for the trailing twelve months (TTM) ended in Feb. 2024 was -0.067 (May. 2023 ) + -0.065 (Aug. 2023 ) + -0.055 (Nov. 2023 ) + -0.068 (Feb. 2024 ) = $-0.26 Mil.
Cannabis Suisse's Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2024 was -0.017 (May. 2023 ) + -0.003 (Aug. 2023 ) + -0.018 (Nov. 2023 ) + -0.023 (Feb. 2024 ) = $-0.06 Mil.
Cannabis Suisse's Cash Flow from Investing for the trailing twelve months (TTM) ended in Feb. 2024 was 0 (May. 2023 ) + 0 (Aug. 2023 ) + 0 (Nov. 2023 ) + 0 (Feb. 2024 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannabis Suisse  (OTCPK:CSUI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Feb. 2024, Cannabis Suisse has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Cannabis Suisse Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Cannabis Suisse's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannabis Suisse (Cannabis Suisse) Business Description

Traded in Other Exchanges
N/A
Address
10 North Neuman Street, Suite A, Jacksonville, FL, USA, 32202
Cannabis Suisse Corp is engaged in the rental of commercial office and industrial space.
Executives
Scott Walker Mcalister director, 10 percent owner, officer: CEO/CFO 10 NORTH NEWNAN STREET, SUITE A, JACKSONVILLE FL 32202